Display options
Cite
Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract. 1997;3(3):140-4doi: 10.4158/EP.3.3.140.
Weber, S. L. (1997). Cushing'S syndrome attributable to topical use of lotrisone. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 3(3), 140-4. https://doi.org/10.4158/EP.3.3.140
Weber, S L. "Cushing'S syndrome attributable to topical use of lotrisone." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 3,3 (1997): 140-4. doi: https://doi.org/10.4158/EP.3.3.140
Weber SL. Cushing'S syndrome attributable to topical use of lotrisone. Endocr Pract. 1997 May-Jun;3(3):140-4. doi: 10.4158/EP.3.3.140. PMID: 15251475.
Copy Download .nbib Format: NLM
Share it on

Endocr Pract. 1997 May-Jun;3(3):140-4. doi: 10.4158/EP.3.3.140.

Cushing'S syndrome attributable to topical use of lotrisone.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

S L Weber

Affiliations

  1. Department of Medicine, Division of Endocrinology, University of Miami, Miami, Florida, USA.

PMID: 15251475 DOI: 10.4158/EP.3.3.140

Abstract

OBJECTIVE: To emphasize the potentially devastating consequences of topical application of corticosteroids.

METHODS: A case report is presented of a previously healthy 38-year-old woman in whom florid Cushing's syndrome developed after prolonged use of Lotrisone.

RESULTS: Four years of continuous topical administration of Lotrisone, a combination antifungal-corticosteroid product, led to the development of Cushing's syndrome. The cream had been applied to less than 10% of the total body surface area without use of occlusive dressings, and the patient had no evidence of liver dysfunction or systemic skin disorder. Laboratory studies revealed an unmeasurable corticotropin level, suppressed or unmeasurable cortisol levels, and suppressed or low-normal 24-hour urine collection values for 17-hydroxy-steroids, 17-ketosteroids, and urinary free cortisol, all of which confirm suppression of the hypothalamic-pituitary-adrenal axis.

CONCLUSION: (1) Betamethasone dipropionate can lead to the development of Cushing's syndrome, even in the absence of enhancing factors. (2) Combination medications can lead to the unintentional use of component agents. (3) Availability of potent corticosteroids as over-the-counter medications allows for inappropriate duration of therapy and inadequate medical supervision.

Publication Types